Sautenet Bénédicte, Tong Allison, Manera Karine E, Chapman Jeremy R, Warrens Anthony N, Rosenbloom David, Wong Germaine, Gill John, Budde Klemens, Rostaing Lionel, Marson Lorna, Josephson Michelle A, Reese Peter P, Pruett Timothy L, Hanson Camilla S, O'Donoghue Donal, Tam-Tham Helen, Halimi Jean-Michel, Shen Jenny I, Kanellis John, Scandling John D, Howard Kirsten, Howell Martin, Cross Nick, Evangelidis Nicole, Masson Philip, Oberbauer Rainer, Fung Samuel, Jesudason Shilpa, Knight Simon, Mandayam Sreedhar, McDonald Stephen P, Chadban Steve, Rajan Tasleem, Craig Jonathan C
1 Sydney School of Public Health, The University of Sydney, Sydney, Australia.2 Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, Sydney, Australia.3 Faculté de Médecine, Université Francois Rabelais, Tours, France.4 Department of Nephrology and Clinical Immunology, Tours Hospital, Tours, France.5 INSERM, U1246, Tours, France.6 Centre for Transplant and Renal Research, Westmead Hospital, Sydney, Australia.7 School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.8 ESRD Network 18, Los Angeles, CA.9 Division of Nephrology, University of British Columbia, Vancouver, Canada.10 Department of Nephrology, Charité - Universitätsmedizin Berlin, Germany.11 Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire, Rangueil, Toulouse, France.12 Transplant Unit, University of Edinburgh, Edinburgh, United Kingdom.13 Department of Medicine, The University of Chicago, Chicago, IL.14 Renal Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.15 Department of Surgery, University of Minnesota, Minneapolis, MN.16 Department of Renal Medicine, Salford Royal NHS Foundation Trust, Salford, United Kingdom.17 Department Community Health Sciences, University of Calgary, Calgary, Canada.18 Department of Nephrology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA.19 Department of Nephrology, Monash Health and Centre for Inflammatory Diseases, Department of Medicine, Monash University, Clayton, Victoria, Australia.20 Department of Medicine, Stanford University School of Medicine, Stanford, CA.21 Department of Nephrology, Christchurch Hospital, Christchurch, New Zealand.22 Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, Scotland, United Kingdom.23 Department of Internal Medicine, Division of Nephrology, University of Vienna, Austria.24 Jockey Club Nephrology and Urology Centre, Princess Margaret Hospital, Hong Kong.25 Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.26 Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.27 Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.28 Selzman Institute for Kidney Health, Section of Nephrology, Baylor College of Medicine, Houston, TX.29 ANZDATA Registry, South Australia Health and Medical Research Institute, Adelaide, Australia.30 Renal Medicine and Transplantation, Royal Prince Alfred Hospital, Sydney, Australia.
Transplantation. 2017 Aug;101(8):1875-1886. doi: 10.1097/TP.0000000000001776.
Inconsistencies in outcome reporting and frequent omission of patient-centered outcomes can diminish the value of trials in treatment decision making. We identified critically important outcome domains in kidney transplantation based on the shared priorities of patients/caregivers and health professionals.
In a 3-round Delphi survey, patients/caregivers and health professionals rated the importance of outcome domains for trials in kidney transplantation on a 9-point Likert scale and provided comments. During rounds 2 and 3, participants rerated the outcomes after reviewing their own score, the distribution of the respondents' scores, and comments. We calculated the median, mean, and proportion rating 7 to 9 (critically important), and analyzed comments thematically.
One thousand eighteen participants (461 [45%] patients/caregivers and 557 [55%] health professionals) from 79 countries completed round 1, and 779 (77%) completed round 3. The top 8 outcomes that met the consensus criteria in round 3 (mean, ≥7.5; median, ≥8; proportion, >85%) in both groups were graft loss, graft function, chronic rejection, acute rejection, mortality, infection, cancer (excluding skin), and cardiovascular disease. Compared with health professionals, patients/caregivers gave higher priority to 6 outcomes (mean difference of 0.5 or more): skin cancer, surgical complications, cognition, blood pressure, depression, and ability to work. We identified 5 themes: capacity to control and inevitability, personal relevance, debilitating repercussions, gaining awareness of risks, and addressing knowledge gaps.
Graft complications and severe comorbidities were critically important for both stakeholder groups. These stakeholder-prioritized outcomes will inform the core outcome set to improve the consistency and relevance of trials in kidney transplantation.
结果报告不一致以及经常遗漏以患者为中心的结果会降低试验在治疗决策中的价值。我们基于患者/照顾者与卫生专业人员的共同优先事项,确定了肾移植中至关重要的结果领域。
在一项三轮德尔菲调查中,患者/照顾者和卫生专业人员使用9点李克特量表对肾移植试验结果领域的重要性进行评分并发表意见。在第2轮和第3轮中,参与者在查看自己的分数、受访者分数分布和意见后重新对结果进行评分。我们计算了中位数、平均数以及评分为7至9分(至关重要)的比例,并对意见进行了主题分析。
来自79个国家的1018名参与者(461名[45%]患者/照顾者和557名[55%]卫生专业人员)完成了第1轮,779名(77%)完成了第3轮。两组在第3轮中符合共识标准(平均数≥7.5;中位数≥8;比例>85%)的前8个结果是移植物丢失、移植物功能、慢性排斥、急性排斥、死亡率、感染、癌症(不包括皮肤癌)和心血管疾病。与卫生专业人员相比,患者/照顾者对6个结果给予了更高的优先级(平均差异为0.5或更大):皮肤癌、手术并发症、认知、血压、抑郁和工作能力。我们确定了5个主题:控制能力与不可避免性、个人相关性、使人衰弱的影响、认识风险以及填补知识空白。
移植物并发症和严重合并症对两个利益相关者群体都至关重要。这些利益相关者优先考虑的结果将为核心结果集提供信息,以提高肾移植试验的一致性和相关性。